Database : MEDLINE
Search on : Bone and Marrow [Words]
References found : 310189 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 31019 go to page                         

  1 / 310189 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 25152120
[Au] Autor:Wang Y; Fu R; Liu H; Wang H; Zhang T; Ding S; Zhang J; Gao S; Liu C; Wang J; Xing L; Wang H; Li L; Liu H; Ruan E; Song J; Wu Y; Guan J; Qu W; Shao Z
[Ad] Address:Department of Hematology, General Hospital,Tianjin Medical University,Tianjin 300052, China....
[Ti] Title:[Memory B (CD5⁺CD19⁺CD27⁺) lymphocyte in patients with immune-related pancytopenia].
[So] Source:Zhonghua Xue Ye Xue Za Zhi;35(8):719-23, 2014 Aug 14.
[Is] ISSN:0253-2727
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:OBJECTIVE: To detect memory B lymphocyte (Bm) in peripheral blood (PB) of immune-related pancytopenia (IRP). METHODS: 86 patients with IRP and 11 health volunteers were enrolled in this study. Bm (CD5⁺CD19⁺CD27⁺) and bone marrow mononucleated cell antibodies (BMMNC-Ab) were determined via fluorescence-activated cell sorting, and clinical outcomes of these patients were analyzed. RESULTS: (1)43 initial patients achieved obvious remission in all 52 initial cases after conventional immunosuppression therapy. 16 relapsed patients with IRP received Rituximab (RTX) and 14 cases achieved obvious remission, among which 7 cases were refractory to conventional immunosuppression therapy, 5 cases exhibited obvious remission, and 2 cases did not respond. Other 18 relapsed cases received conventional immunosuppression therapy and 13 cases achieved obvious remission. (1)The level of Bm in PB in 52 initial patients with IRP was(1.810.97)%, and no significant difference was observed between the initial patients and health volunteers (1.750.55)% (P>0.05). The level of Bm in PB in 34 relapsed patients with IRP was obviously higher than that in the initial IRP patients and health volunteers (P<0.05). Significant difference was observed in the level of Bm in PB in 16 relapsed IRP patients between pre-therapy and post-therapy with RTX (P<0.05). No statistical difference was found between the remission and no-response groups in relapsed patients treated with RTX. RTX regimen produced more effective outcome than conventional immunosuppression therapy, which better eliminated Bm than the latter (P<0.05). Initial patients with IRP who relapsed within a two-year follow-up period had a lower level of Bm in PB compared with unrelapsed patients (P<0.05). Majority of BMMNC- Ab antibodies in relapsed patients were IgG (82.4%) and IgM (69.2%) autoantibodies in patients with initial IRP. CONCLUSION: The level of Bm in PB was associated with relapsed patients with IRP. Bm did not respond to conventional immunosuppression therapy,but responded to RTX.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.3760/cma.j.issn.0253-2727.2014.08.011

  2 / 310189 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25152119
[Au] Autor:Qin X; Baumann I; Chen J; Shen P; Chen J; Yin M
[Ad] Address:Department of Pathology, Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China....
[Ti] Title:[Refractory cytopenia of children and acquired aplastic anemia: a clinical and pathological study of 130 cases].
[So] Source:Zhonghua Xue Ye Xue Za Zhi;35(8):713-8, 2014 Aug 14.
[Is] ISSN:0253-2727
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:OBJECTIVE: To explore the clinical characteristics and histopathological morphology features of bone marrow biopsies between refractory cytopenia of children (RCC) and acquired aplastic anemia (AAA) to facilitate the diagnosis, differential diagnosis and treatment of RCC and AAA. METHODS: We retrospectively analyzed clinical data and histopathological morphology of bone marrow biopsies in RCC or AAA patients referred to our hospital from January 2011 to December 2012. RESULTS: There were totally 130 patients studied. The final diagnoses of them were RCC in 78 cases (60.0%) and AAA in 52 cases (40.0%). The median WBC count, absolute neutrophil count, blood platelet count, hemoglobin level, and reticulocyte count were all higher in RCC children than AAA (P<0.01). All of RCC patients showed hypocellular biopsy specimens, and 84.6% (66/78) of them had cellularity of bone marrow biopsy specimens ranging from 20% to 60%. Patchy pattern distribution was seen in 98.7% (77/78) of RCC cases, and micromegakaryocyte was found in 61.5% (48/78) of RCC cases. All of AAA patients showed severe hypocellular biopsy specimens, and 88.5% (46/52) of them had cellularity of bone marrow biopsy specimens under 5%. Megakaryocyte was not found in 98.1% (51/52) of AAA cases. The response rates of immunosuppressive therapy using CsA rabbit anti- thymocyte globulin androgen traditional Chinese medicine for patients with RCC and AAA were 59.5% and 26.9% at 3 months (P=0.011), and 75.0% and 38.1% at 6 months, respectively (P=0.007). CONCLUSION: RCC patients showed milder cytopenia and bone marrow hyperplasia than AAA. Patchy distribution of hematopoietic cells, erythroid islands with a marked left shift and micromegakaryocytes were decisive histomorphological patterns used to separate RCC from SAA. Immunosuppressive therapy using CsA rabbit anti- thymocyte globulin androgen traditional chinese medicine was an effective therapy in patients with RCC and AAA, and the outcome of immunosuppressive therapy for RCC patients was superior to that of AAA patients.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.3760/cma.j.issn.0253-2727.2014.08.010

  3 / 310189 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25152118
[Au] Autor:Qiao C; Zhou C; Zhang S; Guo R; Zhang F; Qian S; Huan Y; Song Y; Liao H; Li C; Xia S; Sui X; Lu Y; Li J; Li D
[Ad] Address:Department of Hematology, BenQ Medical Center, Nanjing Medical University, Nanjing 210019, China....
[Ti] Title:[Analysis of ND4 gene mutations in acute myelogenous leukemia].
[So] Source:Zhonghua Xue Ye Xue Za Zhi;35(8):708-12, 2014 Aug 14.
[Is] ISSN:0253-2727
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:OBJECTIVE: To investigate the relationship of the mutational status of the ND4 gene and the clinical features of acute myelogenous leukemia (AML) patients with ND4 mutations. METHODS: Using PCR combined with directly sequencing, we identified somatic mutations of ND4 in 121 primary AML patients to couple with their clinical features. RESULTS: There were 58 male patients and 63 female patients (median age 49 years, 10-86 years). Eight of 121 patients (6.6%) with de novo AML were found harboring missense mutation of ND4 gene, including 3 patients with A131V (3/8, 37.5%), 2 patients with A404T (2/8, 25%), 1 patient with F149L(1/8, 12.5%), 1 patient with G242D (1/8, 12.5%) and 1 patient with Y409H (1/8, 12.5%), respectively. Patients with ND4 mutations were associated with good karyotype (P=0.049), regardless of gender, age, white blood cell, hemoglobin, platelet, blast cells of bone marrow or immunophenotype (P>0.05). There were no statistical significance in mutations of FLT3-ITD, NPM1, CEBPA, c-KIT and DNMT3A between patients with ND4 mutation and wild-type (wt) ND4 (P>0.05). The median overall survival of patients with ND4 mutations and wt ND4 were all not reached. The median relapse-free survival were not reached and 29(2-53) months, respectively (P>0.05). There was no significance in the ratio of CR and RR patients between wt ND4 and ND4 mutated groups (P>0.05). CONCLUSION: It was concluded that novel ND4 mutations could be found in de novo AML patients, especially in patients with good karyotype. Thus, ND4 mutations might play an important role in AML prognosis. However, whether the mitochondria dysfunction contribute to leukemogenesis needs to be further investigated.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.3760/cma.j.issn.0253-2727.2014.08.009

  4 / 310189 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25081504
[Au] Autor:Gagala J; Tarczynska M; Gaweda K; Matuszewski L
[Ad] Address:Orthopaedic and Traumatology Department, Medical University of Lublin, ul. Dr K Jaczewskiego 8, 20-954 Lublin, Poland. Electronic address: jacekgagala@gmail.com....
[Ti] Title:The use of osteochondral allograft with bone marrow-derived mesenchymal cells and hinge joint distraction in the treatment of post-collapse stage of osteonecrosis of the femoral head.
[So] Source:Med Hypotheses;83(3):398-400, 2014 Sep.
[Is] ISSN:1532-2777
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Osteonecrosis of the femoral head is an entity which occurs mainly in young and active patients aged between 20 and 50. The success of hip joint preserving treatments ranges from 15% to 50% depending on the stage and amount of osteonecrotic lesion. Total hip replacement is indicated in late post-collapse hips but it has unsatisfactory survival because of the wear and osteolysis in young and active patients. Osteochondral allografts have been reported in the treatment of large articular lesions with defects in underlying bone in knee, talus and shoulder. By combining osteoconductive properties of osteochondral allograft with osteogenic abilities of bone marrow-derived mesenchymal cells it has a potential to be an alternative to an autologous graft. The adjunct of hinged joint distraction should minimize stresses in subchondral bone to promote creeping substitution and prevent femoral head collapse. Unlike current treatment modalities, it would provide both structural support and allow bony and articular substitution.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:IM
[St] Status:In-Data-Review

  5 / 310189 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24962209
[Au] Autor:Tajiri N; Staples M; Kaneko Y; Kim SU; Zesiewicz TA; Borlongan CV
[Ad] Address:Center of Excellence for Aging & Brain Repair, Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, 12901 Bruce B. Downs Blvd., Tampa, FL 33612, USA....
[Ti] Title:Autologous stem cell transplant with gene therapy for Friedreich ataxia.
[So] Source:Med Hypotheses;83(3):296-8, 2014 Sep.
[Is] ISSN:1532-2777
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:We advance the overarching hypothesis that stem cell therapy is a potent treatment for Friedreich's ataxia (FRDA). Here, we discuss the feasibility of autologous transplantation in FRDA, highlighting the need for the successful isolation of the FRDA patient's bone marrow-derived mesenchymal stem cells, followed by characterization that these cells maintain the GAA repeat expansion and the reduced FXN mRNA expression, both hallmark features of FRDA. Next, we discuss the need for assessment of the proliferative capability and pluripotency of FRDA patient's bone marrow-derived mesenchymal stem cells. In particular, we view the need for characterizing the in vitro differentiation of bone marrow-derived mesenchymal stem cells into the two cell types primarily affected in FRDA, peripheral neurons and cardiomyocytes. Finally, we discuss the need to test the application of bone marrow-derived mesenchymal stem cells as potent autologous donor cells for FRDA. The demonstration of the functional correction of the mutated gene in these cells will be a critical endpoint of determining the potential of stem cell therapy in FRDA. We envision a gene-based cell transplant strategy as a likely therapeutic approach for FRDA, involving stable insertion of functional human bacterial artificial chromosomes or BACs containing the intact FXN gene into stem cells, thereafter leading to the expression of frataxin protein in differentiated neurons/cardiomyocytes.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:IM
[St] Status:In-Data-Review

  6 / 310189 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24045918
[Au] Autor:Reilingh ML; Kerkhoffs GM; Telkamp CJ; Struijs PA; van Dijk CN
[Ad] Address:Orthopaedic Research Center Amsterdam, Department of Orthopaedic Surgery, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD, Amsterdam, The Netherlands.
[Ti] Title:Treatment of osteochondral defects of the talus in children.
[So] Source:Knee Surg Sports Traumatol Arthrosc;22(9):2243-9, 2014 Sep.
[Is] ISSN:1433-7347
[Cp] Country of publication:Germany
[La] Language:eng
[Ab] Abstract:PURPOSE: Osteochondral talar defects are infrequent in children, and little is known about the treatment and clinical outcome of these defects. The purpose of this study was to evaluate the clinical and radiographic outcomes of conservative and primary surgically treated osteochondral talar defects in skeletally immature children. METHODS: Thirty-six (97%) of 37 eligible patients with a symptomatic primary osteochondral talar defect were evaluated after a median follow-up of 4years (range 1-12years). Clinical assessment included the Berndt and Harty outcome question, Ogilvie-Harris score, Visual Analog Scale pain score (at rest, during walking and during running), the American Orthopaedic Foot and Ankle Society (AOFAS) score, and the SF-36. Weight-bearing radiographs were compared with preoperative radiographs with the use of an ankle osteoarthritis classification system. RESULTS: Ninety-two per cent of the initially conservatively treated children [mean age 13years (SD 2)] were eventually scheduled to undergo surgery. After fixation of the fragment, seven cases (78%) reported a good Berndt and Harty outcome, and two cases (22%) a fair outcome; the median AOFAS score was 95.0 (range 77-100). After debridement and bone marrow stimulation, 13 cases (62%) reported a good Berndt and Harty outcome, three cases (14%) a fair outcome, and five cases (24%) a poor outcome; the median AOFAS score was 95.0 (range 45-100). No signs of degenerative changes were seen in both groups at follow-up. CONCLUSIONS: Fixation and debridement and bone marrow stimulation of an osteochondral talar defect are both good surgical options after failed conservative treatment. LEVEL OF EVIDENCE: Retrospective case series, Therapeutic, Level IV.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.1007/s00167-013-2685-7

  7 / 310189 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24928698
[Au] Autor:Menon S; Kirkendall ES; Nguyen H; Goldstein SL
[Ad] Address:Center for Acute Care Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. Electronic address: smenon@med.wayne.edu....
[Ti] Title:Acute kidney injury associated with high nephrotoxic medication exposure leads to chronic kidney disease after 6months.
[So] Source:J Pediatr;165(3):522-527.e2, 2014 Sep.
[Is] ISSN:1097-6833
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVE: To assess the development of chronic kidney disease (CKD) after high nephrotoxic medication exposure-associated acute kidney injury (NTMx-AKI) in hospitalized children. STUDY DESIGN: We performed a retrospective cohort study of children exposed to an aminoglycoside for ≥3days or ≥3 nephrotoxic medications simultaneously for the development of CKD at 6months. Follow-up data >6months after acute kidney injury (AKI) were retrieved from electronic health records. Outcomes in children with NTMx-AKI were compared with patients of same age and primary service distribution who were exposed to nephrotoxic medications but did not develop AKI (controls). RESULTS: One hundred patients with NTMx-AKI were assessed (mean age of 9.36.9years). Commonly involved services were bone marrow transplantation/oncology (59%), liver transplantation (13%), and pulmonary (13%). Pre-AKI estimated glomerular filtration rate (eGFR) was 11914.5mL/min/1.73m(2) (range 90-150mL/min/1.73m(2)). Mean discharge eGFR was 105.127.1mL/min/1.73m(2). At 6months after NTMx-AKI, eGFR (n=77) was 113.830.6mL/min/1.73m(2). Sixteen (20.7%) had eGFR of 60-90, 2 (2.6%) had eGFR <60, and 9 (11.6%) had eGFR >150mL/min/1.73m(2) (hyperfiltration). Twenty-four (68.5%) of 35 patients who were assessed for proteinuria had a urine protein-to-creatinine ratio >0.3mg/mg, and 29 (37.6%) had hypertension. Twenty-six (33.7%) patients had CKD (proteinuria or eGFR<60mL/min/1.73m(2)). An additional 28 (36.3%) were considered to be at risk for CKD with hypertension, eGFR between 60 and 90mL/min/1.73m(2), or eGFR >150mL/min/1.73m(2). CKD, hypertension, and proteinuria were more common in the AKI cohort than in controls. CONCLUSIONS: Six months after NTMx-AKI, 70% of patients had evidence of residual kidney damage (reduced eGFR, hyperfiltration, proteinuria, or hypertension). Few underwent a complete evaluation for CKD. With studies showing an association between AKI and CKD, we suggest systematic comprehensive follow-up in children after NTMx-AKI.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:AIM; IM
[St] Status:In-Data-Review

  8 / 310189 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 24857517
[Au] Autor:Ramaswamy K; Hsieh L; Leven E; Thompson MV; Nugent D; Bussel JB
[Ad] Address:Division of Pediatric Hematology/Oncology, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY....
[Ti] Title:Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
[So] Source:J Pediatr;165(3):600-605.e4, 2014 Sep.
[Is] ISSN:1097-6833
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:OBJECTIVES: To determine the safety, tolerability, or efficacy of 2 licensed thrombopoietic agents in children with persistent and chronic immune thrombocytopenia (ITP). STUDY DESIGN: Retrospective analysis approved by the institutional review board of children with ITP not on-study who received thrombopoietin (TPO) therapy; 21 received romiplostim (11 at Children's Hospital of Orange County, 10 at Weill Cornell Medical Center) and 12 received eltrombopag (all at Weill Cornell Medical Center). Primary response measures were platelet counts ≥50 10(9)/L or ≥20 10(9)/L above baseline for 2 consecutive weeks and 50% of platelet counts ≥50 10(9)/L. Duration of treatment and adverse events, including bone marrow myelofibrosis (MF) consensus grades, were tabulated. RESULTS: Twenty-seven of 33 (82%) patients responded to TPO agents, 18 of 21 to romiplostim, and 9 of 12 to eltrombopag, after an average of 3.6 previous ITP therapies. These 27 patients had platelet counts ≥50 10(9)/L and ≥20 10(9)/L above baseline for 2 consecutive weeks; 26 had 50% of platelet counts ≥50 10(9)/L. Duration of romiplostim use ranged from 6 to 44 months (11/18 ongoing) and of eltrombopag 23 to 53 months (7/12 ongoing). One patient on eltrombopag experienced a provoked deep-vein thrombosis at site of ankle fracture. No other serious drug-related adverse events occurred. Among 24 bone marrows, 10 after greater than 2 years of therapy, 23 were normal (MF grades 0-1); 1 was MF-2. CONCLUSION: Retrospective analysis of off-study use of TPO agents in children with mainly chronic ITP showed increases in platelet counts in more than 4 of 5 children. The long-term use of TPO agents, up to 53 months, without tachyphylaxis supports their efficacy. These agents appear safe, effective, and tolerable in children with chronic ITP.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:AIM; IM
[St] Status:In-Data-Review

  9 / 310189 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 25027388
[Au] Autor:Kato J; Kamiya H; Himeno T; Shibata T; Kondo M; Okawa T; Fujiya A; Fukami A; Uenishi E; Seino Y; Tsunekawa S; Hamada Y; Naruse K; Oiso Y; Nakamura J
[Ad] Address:Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan....
[Ti] Title:Mesenchymal stem cells ameliorate impaired wound healing through enhancing keratinocyte functions in diabetic foot ulcerations on the plantar skin of rats.
[So] Source:J Diabetes Complications;28(5):588-95, 2014 Sep-Oct.
[Is] ISSN:1873-460X
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:AIMS/HYPOTHESIS: Although the initial healing stage involves a re-epithelialization in humans, diabetic foot ulceration (DFU) has been investigated using rodent models with wounds on the thigh skin, in which a wound contraction is initiated. In this study, we established a rodent model of DFU on the plantar skin and evaluated the therapeutic efficacy of bone-marrow-derived mesenchymal stem cells (BM-MSCs) in this model. METHODS: The wounds made on the hind paws or thighs of streptozotocin induced diabetic or control rats were treated with BM-MSCs. Expression levels of phosphorylated focal adhesion kinase (pFAK), matrix metaroprotease (MMP)-2, EGF, and IGF-1, were evaluated in human keratinocytes, which were cultured in conditioned media of BM-MSCs (MSC-CM) with high glucose levels. RESULTS: Re-epithelialization initiated the healing process on the plantar, but not on the thigh, skin. The therapy utilizing BM-MSCs ameliorated the delayed healing in diabetic rats. In the keratinocytes cultured with MSC-CM, the decreased pFAK levels in the high glucose condition were restored, and the MMP2, EGF, and IGF-1 levels increased. CONCLUSIONS/INTERPRETATION: Our study established a novel rat DFU model. The impaired healing process in diabetic rats was ameliorated by transplantation of BM-MSCs. This amelioration might be accounted for by the modification of keratinocyte functions.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:IM
[St] Status:In-Data-Review

  10 / 310189 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 25152619
[Au] Autor:Seydoux E; Rothen-Rutishauser B; Nita IM; Balog S; Gazdhar A; Stumbles PA; Petri-Fink A; Blank F; von Garnier C
[Ad] Address:Department of Respiratory Medicine, Inselspital, Bern University Hospital, Department of Clinical Research, University of Bern, Switzerland ; Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland....
[Ti] Title:Size-dependent accumulation of particles in lysosomes modulates dendritic cell function through impaired antigen degradation.
[So] Source:Int J Nanomedicine;9:3885-902, 2014.
[Is] ISSN:1178-2013
[Cp] Country of publication:New Zealand
[La] Language:eng
[Ab] Abstract:INTRODUCTION: Nanosized particles may enable therapeutic modulation of immune responses by targeting dendritic cell (DC) networks in accessible organs such as the lung. To date, however, the effects of nanoparticles on DC function and downstream immune responses remain poorly understood. METHODS: Bone marrow-derived DCs (BMDCs) were exposed in vitro to 20 or 1,000 nm polystyrene (PS) particles. Particle uptake kinetics, cell surface marker expression, soluble protein antigen uptake and degradation, as well as in vitro CD4(+) T-cell proliferation and cytokine production were analyzed by flow cytometry. In addition, co-localization of particles within the lysosomal compartment, lysosomal permeability, and endoplasmic reticulum stress were analyzed. RESULTS: The frequency of PS particle-positive CD11c(+)/CD11b(+) BMDCs reached an early plateau after 20 minutes and was significantly higher for 20 nm than for 1,000 nm PS particles at all time-points analyzed. PS particles did not alter cell viability or modify expression of the surface markers CD11b, CD11c, MHC class II, CD40, and CD86. Although particle exposure did not modulate antigen uptake, 20 nm PS particles decreased the capacity of BMDCs to degrade soluble antigen, without affecting their ability to induce antigen-specific CD4(+) T-cell proliferation. Co-localization studies between PS particles and lysosomes using laser scanning confocal microscopy detected a significantly higher frequency of co-localized 20 nm particles as compared with their 1,000 nm counterparts. Neither size of PS particle caused lysosomal leakage, expression of endoplasmic reticulum stress gene markers, or changes in cytokines profiles. CONCLUSION: These data indicate that although supposedly inert PS nanoparticles did not induce DC activation or alteration in CD4(+) T-cell stimulating capacity, 20 nm (but not 1,000 nm) PS particles may reduce antigen degradation through interference in the lysosomal compartment. These findings emphasize the importance of performing in-depth analysis of DC function when developing novel approaches for immune modulation with nanoparticles.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1408
[Js] Journal subset:IM
[St] Status:In-Data-Review
[do] DOI:10.2147/IJN.S64353


page 1 of 31019 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information